Amivantamab is used for its immunotherapeutic anticancer activity by inhibiting ligand binding, promoting endocytosis and degradation of receptor-antibody complexes, inducing Fc-dependent phagocytosis by macrophages, and mediating antibody-dependent cellular cytotoxicity by natural killer cells.